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The phenomenon of epithelial-mesenchymal transition
(EMT) is a phenotypic switch that allows epithelial tumor
cells to acquire features of mesenchymal cells, including
the ability to migrate and invade and, therefore, to disse-
minate from the primary site. In addition to promoting
tumor dissemination, various reports have demonstrated
that acquisition of features of EMT associates with tumor
resistance to the cytotoxic effects of chemotherapy, radia-
tion, and some targeted therapies. It is not well under-
stood, however, the contribution of EMT to the escape of
tumors from host immune-surveillance and immune-
mediated rejection. Our laboratory has characterized
the T-box transcription factor Brachyury as a tumor-
associated antigen and a regulator of EMT in human
carcinomas. Currently, a Brachyury-based, recombinant
yeast cancer vaccine is ongoing Phase I clinical testing for
the treatment of patients with advanced carcinomas. In
the present study, human epithelial carcinoma cell lines
undergoing EMT via Brachyury over-expression and their
epithelial tumor cell counterparts were comparatively
utilized to evaluate whether EMT imparts resistance to
immune-mediated attack. Our results demonstrate a bell-
shaped relationship between the levels of Brachyury
expression and the susceptibility of human carcinoma cell
lines to lysis by immune cells. While tumor cells with low/
intermediate levels of Brachyury expression are vulnerable
to cell lysis, those with high levels of Brachyury expression
are very resistant to lysis by immune cells. Our results
demonstrate that a high level of Brachyury expression in
human tumor cells reduces their susceptibility to antigen-
specific CD8+ cytotoxic T cells and innate, natural killer
(NK) and lymphokine-activated killer (LAK) cells. The
mechanisms involved in this phenomenon are currently
under investigation, and our results indicate that targeting
the process of EMT may be a successful strategy not only
to interfere with tumor dissemination but also to increase
the effectiveness of immunotherapeutic interventions
against metastatic tumors.
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